Skin Diseases
📧 Sign up to get email alerts when something new happens for Skin Diseases.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2021-03-19EMA Application withdrawn: Dexamethasone Taw (Dexamethasone (sodium phosphate)) — Taw Pharma (Ireland) Ltd
EMA withdrew the application for Dexamethasone Taw (dexamethasone sodium phosphate) by Taw Pharma (Ireland) Ltd.
-
EMA withdrawal · 2020-02-05EMA Application withdrawn: Nuzyra — Paratek Ireland Limited
The EMA status shows withdrawal of the Nuzyra application by Paratek Ireland Limited.
-
CLINICAL_TRIALS withdrawal · 2015-05-29Clinical Trial Update: Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections [NA]
The trial evaluating topical antibiotics to prevent ICU central line-associated bloodstream infections has been withdrawn.
-
EMA withdrawal · 2010-09-22EMA Refused: Zeftera (previously Zevtera) (ceftobiprole medocaril) — Janssen-Cilag International NV
The EMA refused approval for Zeftera (ceftobiprole medocaril) from Janssen-Cilag International NV for skin and soft tissue infections, with …
-
EMA withdrawal · 2009-08-25EMA Application withdrawn: Ramvocid — Targanta Netherlands B.V.
The EMA withdrew the Ramvocid application by Targanta Netherlands B.V. for Gram-positive bacterial infections, skin diseases, and soft tissu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2008-10-24EMA Application withdrawn: Vibativ (telavancin) — Astellas Pharma Europe B. V.
EMA withdrew the application for Vibativ (telavancin) by Astellas Pharma Europe B. V.; therapeutic areas include skin infections and staphyl…
-
EMA withdrawal · 2008-09-10EMA Application withdrawn: Exulett — Pfizer Limited
EMA reports withdrawal of the Exulett application by Pfizer Limited for skin and soft tissue infections and staphylococcal infections.